Advantage Therapeutics | search
Click here to view Advantage Therapeutics news from 60+ newspapers.
Bookmark or Share- Advantage Therapeutics - A new Vantage on Alzheimer’s DiseaseADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US.
- Advantage Therapeutics Inc.Source: Advantage Therapeutics Inc. March 15, 2023 10:18 ET A D vantage Therapeuti cs D evel opi ng Therapi es to Treat N eurodegenerati ve C ondi ti ons w i th Focus on A l zhei mer’ s D i sease C om pany A w aits R egulator y C lear anc e to C onduc t C onfir m ator y P has e 2b T r ial for Lead P r oduc t C andidate
- ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b ...MIAMI, November 27, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging, today announced the first patient enrolled in the Company’s European Phase 2b clinical trial on its lead candidate, AD04 ...
- Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to ...ADvantage Therapeutics is developing AD04™ as a new class of therapeutic for mild Alzheimer’s diseasethat exhibits durable multifaceted effects, including both immediate symptomatic relief and long-term disease-modification.
- OUR TEAM - Advantage TherapeuticsYou may contact ADvantage Therapeutics at: ADvantage Therapeutics Inc. 195 NW 40 th Street Miami, FL 33127
More
